The forecast for cardiac glycosides sales in Italy from 2024 to 2028 suggests a near cessation of sales from 2025 onward, with the value per capita dropping to zero. In 2023, the data is not provided, but a significant decline in 2024 indicates an already minimal presence. From 2024 to 2025, there is a 100% decrease in sales, signifying a complete market exit over the forecasted period.

Future Trends to Watch:

The shift in treatment protocols away from cardiac glycosides due to advancements in alternative therapies.
Monitoring regulatory changes that could impact drug availability or usage.
Watch for potential mergers or acquisitions that may revive interest in this market segment.